Open to all conference attendees.

Employers and purchasers know that PBMs, hospitals, and the 340B drug pricing program drive up drug costs for purchasers and working families. Often, we are paying PBMs and hospitals several times what drug manufacturers actually receive. But even if those abuses are curbed, Americans are likely to continue to pay more for drugs than consumers in other countries. President Trump has proposed radical changes to drug prices, including the “Most Favored Nation” (MFN) policy, which would peg drug prices to those in other industrialized countries. Shawn Gremminger and Steve Ubl will discuss the challenges and opportunities facing drug makers and purchasers, including MFN, direct-to-consumer models, and the drive toward value-based pricing, where drugs are priced according to clinical value and not how much middlemen can extract discounts and fees.